In a Danish nationwide cohort of patients with CD, the prevalence of perianal fistulas decreased in the period from 2010 to 2016. The reason for this needs further elucidation. Only half of the incident cases received biologicals, yet biological treatment was the main expenditure for the entire study population. Healthcare costs for pCF decreased during ...

This study, a register-based Danish population study, investigated the average annual healthcare costs and production values of patients 10 years before and 8 years after diagnosis, and after initiating biologic treatment. ...

Patients with inflammatory bowel disease diagnosed in childhood are at an increased risk of both cancer and mortality compared to the background population. While cancer is the leading cause of death, the risk of suicide is markedly increased. ...

Prospective studies specifically assessing the effectiveness and safety profile of current therapeutic strategies based on a wider use of biologics in inflammatory bowel disease (IBD) are lacking. The overall objectives of I-CARE –a European prospective observationalstudy –are to assess: 1) the long-term safety profile (malignancy, infections) of immunomodulators (IMM), biologics (anti-TNF and vedolizumab) alone or in ...

Decreased health-related quality of life was most prominently associated to bowel frequency during daytime, urgency of defecation and blood in the stool. Other symptoms such as bowel frequency during night-time and arthritis were associated for some health-related quality of life dimensions, and appear to vary between the sexes. Furthermore, female sex was an independent predictor ...

In this Norwegian study Bjoern Moum and colleagues aimed to investigate the drug survival of biologics in a national cohort of patients with Crohn’s disease. Data were collected from the Norwegian Patient Registry (NPR) and the Norwegian Prescription Database. In total, 2444 CD patients were included in the study. After 3 years, the survival rate ...

Karoline Anisdahl, Oslo University Hospital, Norway, and her colleagues aimed to assess whether there was a change over time in the proportion of patients receiving biologics between 2011 and 2016 and if the preferred first-line biologic changed after the introduction of biosimilar infliximab. Click and hear the highlights from the study. ...

In this MEDtalk Brian Bressler present data from amulti-country, retrospective chart review study assessed the effectiveness and safety of vedolizumab compared with anti-tumour necrosis factors  agents in a real-world cohort of biologic-naïve Crohn’s disease patients. Click and hear the result. ...

This Danish population-based cohort study shows an increased risk of T2D both in patients with UC and CD. Whether the significantly higher risk of T2D observed in recent years reflects an impact of current treatment options in IBD remains to be investigated. ...

This study aimed to compare the real-world clinical effectiveness and safety of vedolizumab, a gut-selective anti-α4β7-integrin, and anti-TNF agents in biologic (bio)-naïve ulcerative colitis (UC) patients. Click and hear the results, presented by Andres Yarur. ...